Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes
Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · Apr 4, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how web-based tools can help families communicate better about the risks of hereditary cancer and make it easier for relatives of patients with hereditary cancer conditions to get genetic testing. Hereditary cancers are caused by genetic changes that can run in families, and understanding these risks is important for relatives, as they may also be at higher risk for certain cancers. Currently, only about 20% to 30% of biological relatives choose to get tested after a genetic condition is found in a family member. The trial will use a tool called the Cascade Genetic Testing Platform to improve the way families share information about cancer risks and encourage more relatives to consider genetic testing.
To participate in this study, you must be at least 18 years old, able to read and speak English, and have access to the internet. You should either have a confirmed genetic change linked to a hereditary cancer syndrome from a previous evaluation at the University of Michigan Cancer Genetics Clinic (if you are the patient, referred to as a "proband") or be a biological relative of such a patient who hasn’t yet undergone genetic testing. Participants can expect to use the online tools to help facilitate communication about genetic risks and testing options with their family members. This trial is not yet recruiting, but it aims to make a significant difference in how families are informed about hereditary cancer risks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome
- • PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic
- • PROBANDS: ≥ 18 years old
- • PROBANDS: Able to speak and read English
- • PROBANDS: Access to the internet
- • RELATIVES: Biological relative of proband
- • RELATIVES: ≥ 18 years old
- • RELATIVES: Able to speak and read English
- • RELATIVES: Access to the internet
- • RELATIVES: Have not completed germline genetic testing, per self-report at baseline
- Exclusion Criteria:
- • RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline
About University Of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Elena M Stoffel
Principal Investigator
University of Michigan Rogel Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported